急性脑梗塞早期降纤治疗的临床研究

目的 研究急性脑梗塞早期降纤治疗的临床疗效。方法 124例急性脑梗塞患者随机分成治疗组（63例）与对照组（61例），治疗组在对照组常规使用胞二磷胆硷、血栓通、尼莫地平、阿司匹林等常规药物治疗的基础上，早期加用东菱迪芙治疗。两组治疗前后均做血浆纤维蛋白原测定，并应用神经功能缺损评分标准进行疗效评价。结果 治疗组治疗后血浆纤维蛋白原明显降低：治疗14d后神经功能恢复明显优于对照组．总有效率为83．7％，明显优于对照组（67．21％），两组对比（P〈0．01）。结论 急性脑梗塞早期降纤治疗安全有效．可在临床推广使用。

Clinical Study of Defibrinogen in Treatment of Cerebral Infarction

Objective To evaluate the efficacy and safety of defibrinogen in treatment of cerebral infarction. Methods One hundred and twenty-four patients with acute cerebral infarction were randomly divided into control group (group C, n=63) or study group (group S, n=61). Patients in both groups received citicoline sodium, xueshuantong, nimodipine and aspirin. Batroxobin injection were given on the 1st, 3rd and 5th day for patients in group S. Fibrinogen were measured before and after treatment. The efficacy was evaluate by using neurological functional deficits scales score for all patients. Results The level of fibrinogen decreased after treatment in group S. There were a significantly greater proportion of favorable function outcomes in group S than in group C (83.7% vs 67.21%, P<0.01). Conclusion Defibrinogen was safe and effective in treatment of acute cerebral infarction.